|

SHR-A1811 Clinical Trials

21 actively recruiting trials

Also known as: Trastuzumab-rezetecan

Pipeline

Phase 1: 1Phase 2: 12Phase 3: 5Phase 1/2: 3

Top Sponsors

  • Jiangsu HengRui Medicine Co., Ltd.8
  • Fudan University5
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.3
  • Henan Cancer Hospital2
  • Shengjing Hospital1

Indications

  • Cancer21
  • Breast Cancer13
  • HER2-negative Breast Cancer3
  • Advanced Breast Cancer3
  • Hormone Receptor Positive Tumor2

Other21 trials

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1/2
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Phase 3
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Phase 2
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Phase 3
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
Phase 2
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Phase 3
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Phase 1
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Phase 2
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2
Reverse Triple Negative Immune Resistant Breast Cancer
Phase 2
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Phase 3
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Phase 3
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Phase 1/2
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases
Phase 2
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.